Literature DB >> 12474638

Hyperuricosuric calcium nephrolithiasis.

Carsten M Sorensen1, Paramjit S Chandhoke.   

Abstract

Since the findings of Yü and Gutman [1], the hyperuricosuric calcium stone former is a unique clinical entity. While an impressive number of clinical and epidemiologic studies implicate hyperuricosuria in calcium stone formation, the exact physicochemical mechanism by which uric acid affects calcium oxalate crystallization has not been proven. Allopurinol decreases stone recurrences and is the drug of choice for patients with isolated HCN.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12474638     DOI： 10.1016/s0889-8529(02)00038-5

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  9 in total

Review 1.  Nephrolithiasis in children.

Authors:  Mary Ann Cameron; Khashayar Sakhaee; Orson W Moe
Journal:  Pediatr Nephrol       Date:  2005-08-23       Impact factor: 3.714

2.  Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder.

Authors:  Michael R Wiederkehr; Orson W Moe
Journal:  Clin Rev Bone Miner Metab       Date:  2011-12

Review 3.  ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis.

Authors:  T M Reynolds
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

4.  Label-Free Uric Acid Estimation of Spot Urine Using Portable Device Based on UV Spectrophotometry.

Authors:  Tsung-Jui Lin; Kai-Ting Yen; Chien-Fan Chen; Shuo-Ting Yan; Kuan-Wei Su; Ya-Ling Chiang
Journal:  Sensors (Basel)       Date:  2022-04-14       Impact factor: 3.847

5.  Prediction of the Uric Acid Component in Nephrolithiasis Using Simple Clinical Information about Metabolic Disorder and Obesity: A Machine Learning-Based Model.

Authors:  Hao-Wei Chen; Yu-Chen Chen; Jung-Ting Lee; Frances M Yang; Chung-Yao Kao; Yii-Her Chou; Ting-Yin Chu; Yung-Shun Juan; Wen-Jeng Wu
Journal:  Nutrients       Date:  2022-04-27       Impact factor: 6.706

6.  Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.

Authors:  Haibo Yu; Xinying Liu; Yaxiang Song; Jiafen Cheng; Hui Bao; Ling Qin; Xuan Zhou; Ling Wang; Ai Peng
Journal:  Clin Exp Nephrol       Date:  2018-05-14       Impact factor: 2.801

Review 7.  Drosophila melanogaster as an emerging translational model of human nephrolithiasis.

Authors:  Joe Miller; Thomas Chi; Pankaj Kapahi; Arnold J Kahn; Man Su Kim; Taku Hirata; Michael F Romero; Julian A T Dow; Marshall L Stoller
Journal:  J Urol       Date:  2013-03-07       Impact factor: 7.450

8.  Nanouric acid or nanocalcium phosphate as central nidus to induce calcium oxalate stone formation: a high-resolution transmission electron microscopy study on urinary nanocrystallites.

Authors:  Jie Gao; Jun-Fa Xue; Meng Xu; Bao-Song Gui; Feng-Xin Wang; Jian-Ming Ouyang
Journal:  Int J Nanomedicine       Date:  2014-09-16

9.  Dose-response relationship between higher serum calcium level and higher prevalence of hyperuricemia: A cross-sectional study.

Authors:  Zhichen Liu; Xiang Ding; Jing Wu; Hongyi He; Ziying Wu; Dongxing Xie; Zidan Yang; Yilun Wang; Jian Tian
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.